Market Overview

Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency

Related ARWR
10 Stocks Moving In Monday's After-Hours Session
'We're Confident Arrowhead's ARC-520 Is Active Drug For HBV,' Piper Jaffray Says
Top 2 Trade Alert Ideas October 7: Spark's Pullback, Synta Catalyst, M&A Activity (Seeking Alpha)

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application U.S. 13/032,029 entitled, “Compositions for Targeted Delivery of siRNA.” The patent broadly covers compositions, methods, and uses for a new formulation of Arrowhead's Dynamic Polyconjugate (DPC) siRNA delivery platform, where attachment of siRNA and delivery vehicle is not required to produce high-level, efficient knockdown of target genes. The new IP expands the DPC platform and is used in Arrowhead's ARC-520 candidate in development for chronic hepatitis B virus (HBV) infection.

Posted-In: News Legal


Related Articles (ARWR)

Get Benzinga's Newsletters